Libtayo® (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer
Approval marks second first-line indication in NSCLC and fifth indication for Libtayo® in Canada TORONTO, ON — /CNW/ — sanofi-aventis Canada Inc. (Sanofi Canada) is pleased to announce that Health… Read More




